The effects of interleukin-8, VEGF and CFH polymorphisms on the long-term response to bevacizumab therapy in exudative age-related macular degeneration

Recent findings from observational epidemiologic studies have raised concern about a possible adverse effect of regular aspirin use in age-related macular degeneration (AMD), and in particular neovascular AMD, which is the leading cause of severe irreversible blindness in the US. In this report, we consider these findings in light of the relative strengths and limitations of observational studies and randomized trials. While the findings are important and warrant further investigation, the inherent limitations of observation studies, most notably uncontrolled confounding, preclude an interpretation of causality. Alternatively, the most reliable evidence with which to evaluate the effects of regular aspirin use in AMD will derive from well-designed randomized trials of sufficient size and duration.

Download Full-text

LONG-TERM REMISSION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH AS-NEEDED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

Retina ◽

10.1097/iae.0000000000001572 ◽

2018 ◽

Vol 38 (3) ◽

pp. 516-522 ◽

Cited By ~ 5

Author(s):

Ilkay Kilic Muftuoglu ◽

Mostafa Alam ◽

Qi Sheng You ◽

Raouf Gaber ◽

Hema L. Ramkumar ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Macular Degeneration ◽

Age Related Macular Degeneration ◽

Vascular Endothelial ◽

Age Related ◽

Factor Therapy ◽

Growth Factor Therapy ◽

Endothelial Growth Factor

Download Full-text

Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration

Ophthalmology ◽

10.1016/j.ophtha.2018.08.023 ◽

2019 ◽

Vol 126 (1) ◽

pp. 64-74 ◽

Cited By ~ 11

Author(s):

Vuong Nguyen ◽

Vincent Daien ◽

Robyn Guymer ◽

Stephanie Young ◽

Alex Hunyor ◽

...

Keyword(s):

Visual Acuity ◽

Macular Degeneration ◽

Treatment Response ◽

Initial Treatment ◽

Age Related Macular Degeneration ◽

Age Related

Download Full-text

Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2021-319054 ◽

2021 ◽

pp. bjophthalmol-2021-319054

Author(s):

Brice Nguedia Vofo ◽

Gala Beykin ◽

Jaime Levy ◽

Itay Chowers

Keyword(s):

Macular Degeneration ◽

Vision Loss ◽

Age Related Macular Degeneration ◽

Long Term Outcome ◽

Risk Alleles ◽

Macular Atrophy ◽

Anti Vegf ◽

Age Related

AimsTo evaluate the long-term functional and anatomical outcomes of neovascular age-related macular degeneration (nvAMD) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) for up to 10 years, and to identify associated risk factors.MethodsClinical and optical coherence tomography findings were retrieved for nvAMD cases treated with intravitreal anti-VEGF compounds using a treat-and-extend protocol. In addition, the major risk alleles for AMD in the CFH (rs1061170), HTRA1 (rs1200638) and C3 (rs2230199) genes were genotyped.ResultsFrom 276 eligible eyes in 206 patients, 80 eyes (29%) in 66 patients (32.0%) had a follow-up period of ≥8 years and were included in this study. Over a 10-year period, 73.3±28.0 (mean±SD) anti-VEGF injections were administered. Best-corrected visual acuity (BCVA; LogMAR) deteriorated from 0.55±0.53 at baseline to 1.00±0.73 at 10 years (p<0.0005). Central subfield thickness (CST) decreased from 415.8±162.1 µm at baseline to 323±113.6 µm (p<0.0005) after three monthly injections and remained lower than baseline throughout the follow-up period. Visual outcome was associated with BCVA and intraretinal fluid (IRF) at baseline, macular atrophy, and macular thinning at follow-up. The decrease in CST was inversely correlated with the number of CFH and/or C3 risk alleles carried by the patient (Pearson’s r: −0.608; p=0.003).ConclusionsPatients with nvAMD who received anti-VEGF therapy for 10 years developed substantial vision loss associated with the presence of IRF at baseline and macular atrophy. Major risk alleles for AMD in two complement genes were associated with a reduced long-term reduction in macular thickness.

Download Full-text